Literature DB >> 708013

Antimicrobial susceptibility and selection of resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices.

G L Archer.   

Abstract

Twenty-seven isolates of Staphylococcus epidermidis from patients with prosthetic valve endocarditis or infected cerebrospinal fluid shunts were examined for susceptibility to antimicrobial agents. Subpopulations resistant to 20 and 100 mug of methicillin per ml were present in 63% of the isolates (methicillin-resistant isolates). Subpopulations resistant to 20 mug of nafcillin and cephalothin per ml were found in every methicillin-resistant isolate but with frequencies (10(-5.0 +/- 0.5) and 10(-6.4 +/- 0.9), respectively) which were not always detectable by susceptibility testing. Resistance to >/=1.6 mug of penicillin per ml was found in 80% of isolates. Cephalothin, cefazolin, and cefamandole were more active than cefoxitin or cephradine, and gentamicin was more active than tobramycin or amikacin; rifampin was the single most active agent against all isolates. There was no difference in susceptibility between prosthetic valve endocarditis and cerebrospinal fluid shunt infection isolates. Among methicillin-resistant isolates, the phenotypic expression of resistance to methicillin or nafcillin but not to cephalothin could be enhanced by 48 h of incubation with each drug. Isolates containing no methicillin-resistant subpopulations were killed by incubation with methicillin, nafcillin, or cephalothin. High-level resistance to rifampin emerged in both methicillin-resistant and methicillin-sensitive isolates after 8 to 24 h of incubation with this drug. The presence or absence of antibiotic-resistant subpopulations among S. epidermidis isolates and their selection during treatment should be considered when therapy is devised.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708013      PMCID: PMC352464          DOI: 10.1128/AAC.14.3.353

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  CHARACTERISTICS OF METHICILLIN-RESISTANT STAPHYLOCOCCI.

Authors:  R SUTHERLAND; G N ROLINSON
Journal:  J Bacteriol       Date:  1964-04       Impact factor: 3.490

2.  Plasmid-mediated resistance to gentamicin in Staphylococcus aureus.

Authors:  D O Wood; M J Carter; G K Best
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

3.  Interaction between rifampicin and trimethoprim in vitro and in experimental infections.

Authors:  V Arioli; M Berti; G Carniti; E Rossi
Journal:  J Antimicrob Chemother       Date:  1977-01       Impact factor: 5.790

4.  Prosthetic valve endocarditis. Analysis of 38 cases.

Authors:  W E Dismukes; A W Karchmer; M J Buckley; W G Austen; M N Swartz
Journal:  Circulation       Date:  1973-08       Impact factor: 29.690

5.  Methicillin-resistant staphylococci.

Authors:  K Jensen
Journal:  Lancet       Date:  1968-11-16       Impact factor: 79.321

6.  Endocarditis due to Micrococci and Staphylococcus epidermidis.

Authors:  T F Keys; W L Hewitt
Journal:  Arch Intern Med       Date:  1973-08

7.  Vancomycin. A second look.

Authors:  A L Esposito; R A Gleckman
Journal:  JAMA       Date:  1977-10-17       Impact factor: 56.272

8.  In vitro activity of cephalosporins against methicillin-resistant, coagulase-negative staphylococci.

Authors:  M Laverdiere; P Peterson; J Verhoef; D N Williams; L D Sabath
Journal:  J Infect Dis       Date:  1978-03       Impact factor: 5.226

9.  Reliability of the microdilution technic for detection of methicillin-resistant strains of staphylococcus aureus.

Authors:  A L Barry; R E Badal
Journal:  Am J Clin Pathol       Date:  1977-05       Impact factor: 2.493

10.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

View more
  60 in total

1.  Disposition and dosage regimen of cephaloridine in calves.

Authors:  R K Chaudhary; A K Srivastava
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

Review 2.  Coagulase-negative staphylococci and the epidemiological typing of Staphylococcus epidermidis.

Authors:  J T Parisi
Journal:  Microbiol Rev       Date:  1985-06

Review 3.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Prevention of hydrocephalus shunt catheter colonisation in vitro by impregnation with antimicrobials.

Authors:  R Bayston; N Grove; J Siegel; D Lawellin; S Barsham
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

5.  Comparison of various methods for differentiation of staphylococci and micrococci.

Authors:  J S Baker
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

6.  Antibiotic-resistant Staphylococcus epidermidis in patients undergoing cardiac surgery.

Authors:  G L Archer; M J Tenenbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  In vitro susceptibilities of four species of coagulase-negative staphylococci.

Authors:  R J Fass; V L Helsel; J Barnishan; L W Ayers
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

8.  Detection of the Staphylococcal mecA gene by chemiluminescent DNA hybridization.

Authors:  C P Kolbert; J E Connolly; M J Lee; D H Persing
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

9.  Classification and characteristics of coagulase-negative, methicillin-resistant staphylococci.

Authors:  B J Wilkinson; S Maxwell; S M Schaus
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

10.  Species identification of coagulase-negative staphylococcal isolates from blood cultures.

Authors:  R H Eng; C Wang; A Person; T E Kiehn; D Armstrong
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.